POMDOCTOR LIMITED Class A Ordinary Shares
8 hedge funds and large institutions have $229K invested in POMDOCTOR LIMITED Class A Ordinary Shares in 2025 Q4 according to their latest regulatory filings, with 8 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.65% more ownership
Funds ownership: 0% → 0.65% (+0.65%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XTX Topco
George Town,
Cayman Islands
|
+$1.34M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$802K |
| 3 |
Millennium Management
New York
|
+$225K |
| 4 |
HRT Financial
New York
|
+$211K |
| 5 |
Caitong International Asset Management
Hong Kong
|
+$134K |
Top Sellers
POM Hedge Fund Activity: Q4 2025 in Review
8 of the 8,307 institutional investors tracked by Wall St. Rank reported a position in POMDOCTOR LIMITED Class A Ordinary Shares (POM) for Q4 2025, worth a combined $229K.
Buyers outnumbered sellers: 8 funds opened new POM positions and 0 closed out — a net gain of 8 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was XTX Topco, opening a new position worth an estimated $1.34M.
- 8 institutional investors held POMDOCTOR LIMITED Class A Ordinary Shares (POM) as of Q4 2025, up from 0 in Q3 2025.
- Funds reported $229K of POMDOCTOR LIMITED Class A Ordinary Shares stock for Q4 2025.
- 8 funds opened new POMDOCTOR LIMITED Class A Ordinary Shares positions in Q4 2025 and 0 closed out, a net change of +8 holders.
- The largest POMDOCTOR LIMITED Class A Ordinary Shares buyer in Q4 2025 was XTX Topco, an estimated $1.34M added.
Based on aggregated 13F filings for Q4 2025.